Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2021-01-14 Regulatory Filings
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 7143L' and contains language typical of regulatory exchange announcements, such as 'National Storage Mechanism' and references to the 'London Stock Exchange'. The content specifically details a 'Second Price Monitoring Extension' related to trading activity. This type of short, specific, and immediate regulatory notification that doesn't fit into the major financial report categories (like 10-K, IR, ER) is best classified under the general regulatory announcement category, RNS. The document length is very short (1940 chars), supporting the idea that it is a brief announcement rather than a full report.
2021-01-14 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1923 characters) and contains the header 'RNS Number : 7123L' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Price Monitoring Extension' related to trading auctions, which is a specific, immediate operational announcement rather than a comprehensive financial report (like 10-K or IR) or a standard corporate action (like DIV or ER). Since it is a general regulatory announcement distributed via the RNS system that doesn't fit into the more specific categories (like DIRS, MANG, or DIV), the most appropriate classification is the general regulatory filing fallback category.
2021-01-14 English
Total Voting Rights Update
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content announces the 'Total Voting Rights Update' as of 31 December 2020, citing compliance with the FCA's Disclosure and Transparency Rule 5.6.1, and provides the total number of issued shares. This type of mandatory regulatory disclosure, which is not a full financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or SHA), fits best under the general regulatory announcement category. Since 'RNS' is the source and the filing is a standard regulatory update, the most appropriate code is RNS, which serves as the general regulatory filing fallback.
2020-12-31 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is identified by the header 'RNS Number : 5226J' and contains the standard form 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership thresholds. The content explicitly details the 'Total positions of person(s) subject to the notification obligation' and the percentage of voting rights held. This directly corresponds to the definition of a Major Shareholding Notification.
2020-12-22 English
Investor Presentation
Investor Presentation Classification · 98% confidence The document is explicitly titled "Investor Presentation" and announces that a recording of an online company presentation delivered by the CEO is now available on the company website, along with the published Q&A. This content directly relates to materials shared with investors regarding company performance and strategy, fitting the definition of an Investor Presentation (IP). Although it mentions the RNS number and distribution service, the core subject matter is the availability of the presentation recording, not the announcement of the report itself (RPA) or a general regulatory filing (RNS). Since 'IP' is a specific category for investor presentations, it is the most accurate classification.
2020-12-21 English
Grant of share options to the CEO
Regulatory Filings Classification · 98% confidence The document is an official announcement disseminated via RNS (RNS Number: 2359J) on December 18, 2020. The content explicitly details the 'Grant of share options to the Chief Executive Officer' (Tim Watts) under a share plan, including the number of shares, vesting dates, and performance conditions. This type of transaction report, specifically concerning personal share transactions by a director/executive (PDMR), falls directly under the definition of Director's Dealing (DIRS). Although it is an RNS announcement, the specific nature of the content (insider trade/option grant) makes DIRS the most precise classification over the general RNS fallback.
2020-12-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.